SecBot SecBot

ELUT

ELUTIA INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001708527 Biotech & Drug Discovery
$0.8230 +0.00 (+0.37%)
Nov 16 4:00 PM ET · prev $0.8200
Market cap
$36.4M
Nano cap
Median target
$5.00
+508% · range $5.00–5.00
1 year
+12.7%
from $0.7300 · Nov 17
30 days
+1.0%
from $0.8150
52-week range
$0.5050–1.22
−33% from high · low Dec 17
Avg volume 20D
76.7K
Nov 10 spike 298.1K
Short interest
33.7K
≈0.1% of shares · +119.6%
Days to cover
1.0
at average volume
Insider net
+$95.0K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $95.0K at an average $1.06. No open-market sales. Price is 22% below their cost.

  • InstitutionsMIXED

    Q3 2026: 2 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.130 → −$0.160 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +119.6% to 33.7K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCTRIM111,400$88.0K
JANE STREET GROUP, LLCADD61,860$48.9K
UBS Group AGDOUBLED2,325$1.8K
RENAISSANCE TECHNOLOGIES LLCDOUBLED201,816$197.7K
VANGUARD FIDUCIARY TRUST COADD172,446$169.0K
BlackRock, Inc.ADD167,857$164.4K
JANE STREET GROUP, LLCTRIM44,697$43.8K
NORTHERN TRUST CORPADD44,670$43.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Sep 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +508%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 10, 2025Lake Street
MAINTAIN
MAINTAINBuy
May 9, 2025Lake Street
MAINTAIN
MAINTAINBuy
Mar 7, 2025Cantor Fitzgerald
REITERATE
REITERATEOverweight
Nov 15, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Sep 6, 2024Cantor Fitzgerald
REITERATE
REITERATEOverweight
Aug 8, 2024Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$95.0K
bought · 2 insiders
$0
sold · 0 insiders
−22.0%
vs their $1.06 cost
DateInsiderTypeValue
Nov 10, 2026
Colpman David
Director
Nov 10, 2026
AWARD117,000 sh
Nov 10, 2026
Ferguson Matthew
CHIEF FINANCIAL OFFICER
Nov 10, 2026
AWARD446,000 sh
Nov 10, 2026
Mills C Randal
PRESIDENT AND CEO
Nov 10, 2026
AWARD895,000 sh
Nov 10, 2026
NEELS GUIDO J
Director
Nov 10, 2026
AWARD117,000 sh
Nov 10, 2026
RAKIN KEVIN
Director
Nov 10, 2026
AWARD176,000 sh
Nov 10, 2026
Makes Brigid
Director
Nov 10, 2026
AWARD117,000 sh
Nov 10, 2026
Williams Michelle LeRoux
CHIEF SCIENTIFIC OFFICER
Nov 10, 2026
AWARD446,000 sh
Sep 10, 2026
Mills C Randal
PRESIDENT AND CEO
Sep 10, 2026
EXERCISE27,083 sh

Earnings setup

Estimates
−$0.16
EPS estimate, this quarter
−23%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.16-$0.16–-$0.16-23.1%$1.0M
Next Q-$0.15-$0.15–-$0.15No data$0.00
Current FY-$0.66-$0.66–-$0.66-4.8%$7.5M
Next FY-$0.63-$0.63–-$0.63-16.7%$4.3M

Short side

FINRA· Oct 30, 2026
33,661
shares short
+119.6%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 Insider
Colpman David was granted 117,000 shares
Director
Nov 10, 2026 Insider
Ferguson Matthew was granted 446,000 shares
CHIEF FINANCIAL OFFICER
Nov 10, 2026 Insider
Mills C Randal was granted 895,000 shares
PRESIDENT AND CEO
Nov 5, 2026 SEC
Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but net loss from continuing operations widened to $6.5M from…
PRESS-RELEASE · Impact 4/10
Nov 5, 2026 Earnings
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia Reports Q3 2026 Results: As Plastic Surgeons Cite Infection Risk at National Meeting, NXT-41x
Nov 5, 2026 SEC
Elutia reported Q3 2026 net sales of $1.1M (+20.4% YoY) but a net loss from continuing operations of $6.5M…
8-K · Impact 5/10
Oct 22, 2026 SEC
Elutia Inc. announced it will report its Q3 2026 results on November 5, 2026.
PRESS-RELEASE · Impact 1/10
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · TRIM
111,400 shares ($88.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 5, 2026
Earnings
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia Reports Q3 2026 Results: As Plastic Surgeons Cite Infection Risk at National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through…
Nov 5, 2026
Earnings result
ELUT Q3 2026 Earnings: EPS $-0.14 (+8.5% vs est)
Oct 22, 2026
Earnings
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Elutia announced that it will release its third quarter 2026 financial results after market close on Thursday, November 5, 2026....
Oct 1, 2026
Press release
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston…
Sep 2, 2026
Press release
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia to participate in Lake Street and H.C. Wainwright investor conferences, highlighting its work to address post-surgical infection.

SecBot reports

7 filings · 0 bullish · 0 bearish · 1 mixed · 6 neutral
All ELUT filing & press-release reports (7)